Welcome to our dedicated page for Neuronetics news (Ticker: STIM), a resource for investors and traders seeking the latest updates and insights on Neuronetics stock.
Neuronetics, Inc. (NASDAQ: STIM) is a commercial stage medical technology and healthcare company focused on neurohealth and psychiatric disorders, and its news flow reflects this focus. The company develops and markets the NeuroStar Advanced Therapy System, a non-drug, noninvasive transcranial magnetic stimulation (TMS) treatment used in office-based settings, and operates Greenbrook TMS treatment centers across the United States. News about Neuronetics often centers on clinical use of NeuroStar TMS, payer coverage decisions, and developments at its Greenbrook clinics.
Investors following STIM news can expect regular updates on quarterly financial and operating results, as the company reports revenue by geography and product category, including NeuroStar system sales, treatment sessions, and U.S. clinic revenue. Press releases also cover changes to its capital structure and credit facilities, such as amendments to its agreement with Perceptive Credit Holdings IV, LP, as well as at-the-market equity offerings and related capital-raising activities.
Company announcements frequently highlight health policy and reimbursement milestones, including expanded coverage for TMS therapy by New York State Medicaid and TRICARE West for specific patient populations with major depressive disorder. Neuronetics also reports on partnerships and agreements that expand access to NeuroStar TMS, such as an exclusive three-year collaboration with Elite DNA Behavioral Health, under which Neuronetics becomes the sole provider of TMS devices across that network and offers operational and patient-support services using the Greenbrook platform.
Additional STIM news items include participation in investor conferences, leadership and executive appointments, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), and publications of real-world clinical data from the NeuroStar outcomes databases. For readers tracking Neuronetics, this news page aggregates these developments so they can monitor financial performance, payer coverage trends, clinical evidence, and corporate actions related to NeuroStar TMS and Greenbrook treatment centers.
Neuronetics, a medical technology company, reported strong Q1 2022 results with revenues of $14.2 million, exceeding guidance. This marks a 15% increase year-over-year, driven by a 108% increase in NeuroStar System revenue. Notable achievements include FDA clearance for treating Obsessive-Compulsive Disorder and long-term partnerships with Greenbrook TMS and Transformations Care Network.
Despite the growth, the company faced challenges, including a net loss of $10.8 million and a decrease in treatment session revenue by 2%. They expect full-year revenue between $58.0 million and $62.0 million.
Neuronetics, Inc. (NASDAQ: STIM) has announced an extended commercial partnership with Transformations Care Network, enhancing access to NeuroStar systems, which provide transcranial magnetic stimulation (TMS) for mental health treatment. The partnership aims to support the growing number of Americans facing mental health disorders, facilitating better patient access to care. Neuronetics, a leader in TMS technology, emphasizes its commitment to improving quality of life through non-invasive treatment options backed by extensive clinical research.
Neuronetics (NASDAQ: STIM) announced its participation as the only Platinum Sponsor at the Clinical TMS Society Annual Meeting in Chicago from May 12-14, 2022. The company will present new findings from the NeuroStar Outcomes Registry, the largest depression outcomes registry globally. Key discussions include the impact of transcranial magnetic stimulation (TMS) on reducing anxiety in patients with major depressive disorder. Additionally, NeuroStar has recently received FDA clearance for its TMS therapy as an adjunct treatment for Obsessive-Compulsive Disorder (OCD).
Neuronetics, Inc. (NASDAQ: STIM) has filed a federal lawsuit against Brainsway Ltd. for unfair competition, claiming the company misrepresented efficacy data regarding its NeuroStar Advanced Therapy for treating anxious depression. Neuronetics alleges that Brainsway manipulated data by comparing incomplete treatment results with aggregated full-course data from separate studies, misleading clinicians and patients. The lawsuit seeks monetary damages and injunctive relief. CEO Keith J. Sullivan emphasizes the company's commitment to defending its data integrity and improving mental health treatment standards.
Neuronetics, Inc. (NASDAQ: STIM) announced the granting of inducement awards to eight new employees, in accordance with NASDAQ Listing Rule 5635(c)(4). The awards consist of 152,939 Restricted Stock Units (RSUs), valued at the closing trading price on Nasdaq, vesting in three equal installments over three years. This move aims to enhance employee retention and incentivize new hires. Neuronetics is focused on improving mental health through innovative treatments, highlighted by its FDA-cleared NeuroStar Advanced Therapy system, which has delivered over four million treatments for depression.
Neuronetics, a leader in neurohealth technology, will release its first quarter 2022 financial results on May 12, 2022, before the market opens. A conference call to discuss these results is scheduled for the same day at 8:30 a.m. ET, accessible via a webcast on their investor relations site. Neuronetics offers the NeuroStar Advanced Therapy system, a leading treatment for major depressive disorder, with over four million treatments delivered. The system is FDA-cleared and backed by extensive clinical research.
Neuronetics (NASDAQ: STIM) and Greenbrook TMS Inc. have entered a five-year commercial agreement to enhance their collaboration in TMS therapy. This agreement allows Greenbrook to exclusively purchase TMS devices from Neuronetics, which will in turn provide marketing support and better pricing. Greenbrook operates 149 treatment centers and has delivered over 790,000 TMS treatments to patients with depression. The partnership aims to increase awareness of NeuroStar therapy and improve patient access, amid rising mental health concerns in America.
Neuronetics, Inc. (NASDAQ: STIM) announced the granting of inducement awards to five new non-executive employees, approved by its Compensation Committee under NASDAQ Listing Rule 5635(c)(4). The company awarded 38,252 Restricted Stock Units (RSUs), valued at the grant date fair value of its common stock, which will vest in three equal installments over three years. Neuronetics is recognized for its NeuroStar Advanced Therapy system, a leading non-invasive treatment for major depressive disorder, with over four million treatments delivered.
Neuronetics, Inc. (NASDAQ: STIM) reported its financial and operational results for Q4 and FY 2021, with Q4 revenue at $15.0 million, surpassing guidance. The company achieved a 12% annual revenue increase, totaling $55.3 million. U.S. treatment session revenue rose by 20% year-over-year, but U.S. NeuroStar Advanced Therapy System sales declined by 22%. Despite positive operational highlights like the MT Cap clearance, increased marketing effectiveness, and improved gross margins, the company faced a net loss of $31.2 million for 2021. For FY 2022, revenue is projected between $58.0 million and $62.0 million.
Neuronetics has announced a $14.5 million investment to enhance education for patients and physicians about NeuroStar® Advanced Therapy for treating major depressive disorder (MDD). Launched on March 3, 2022, the campaign, titled “Tap into a New Possibility,” aims to raise awareness of depression's impact and the treatment options available. The multi-channel strategy seeks to reach individuals struggling with MDD, highlighting the effectiveness of NeuroStar, which has delivered over 4.3 million treatments. This initiative underscores the company’s commitment to mental health.